nach oben

International Journal of Clinical Oncology

Erschienen in:

01.08.2010 | Original Article

Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings

verfasst von: Yan Chen, Mingang Ying, YanSong Chen, Minhua Hu, Yingying Lin, Dedong Chen, Xiaoli Li, Ming Zhang, Xia Yun, Ji Zhou, Ellen He, Sven Skog

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Thymidine kinase 1 in serum (STK1) has been found to be a reliable proliferation marker in clinical trials. In this study, we examined the significance of STK1 in routine clinical settings.

Methods

The concentration of STK1 was determined by a sensitive dot blot ECL assay. The STK1 value was correlated to clinical stage and reactions and used for monitoring the outcome of surgery and/or multidrug chemotherapy of 1,247 patients with five different types of carcinomas (lung, esophagus, gastric, head and neck, and thyroid) in routine clinical settings.

Results

The STK1 values correlated with the clinical stage in patients with lung, esophagus, thyroid, and gastric carcinomas. After treatment, STK1 declined in all tumor groups after treatments (P < 0.01). The STK1 was low (<2 pM) or decreasing during treatment in patients with clinical reactions of complete response (CR) or partial response (PR), but high (>2 pM) or increasing in patients with stable disease (SD) or progressive disease (PD), some of them showing metastasis. STK1 also reflected the differences in clinical reactions when surgery and chemotherapy were compared.

Conclusion

We concluded that the concentration of TK1 in serum correlates to clinical stages and clinical reactions and monitors the effect of tumor therapies, not only in controlled clinical trials, but also in routine clinical settings.

Nur mit Berechtigung zugänglich

Eissa S (1998) Tumor marker. Chapman & Hall, New York, pp 94–102, 134–137

Tocchi A, Costa G, Lepre L et al (1998) The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer. J Cancer Res Clin Oncol 124:450–455CrossRefPubMed

Ychou M, Duffour J, Kramer A et al (2000) Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 16:105–110PubMed

Dehaghani AS, Ghiam AF, Hosseini M et al (2007) Factors influencing serum concentration of CA125 and CA15-3 in iranian healthy postmenopausal women. Pathol Oncol Res 13:360–364CrossRefPubMed

Pang RW, Joh JW, Johnson PJ et al (2008) Biology of hepatocellular carcinoma. Ann Surg Oncol 15:962–971CrossRefPubMed

Ulmert D, Cronin AM, Bjork T et al (2008) Prostatic-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6:6. doi:10.1186/1741-7015-6-6 CrossRefPubMed

Cheung KL, Evans AJ, Robertson JF (2001) The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat 67:273–278CrossRefPubMed

Hwa HL, Kuo WH, Chang LY et al (2008) Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models. J Eval Clin Pract 14:275–280CrossRefPubMed

Locker GY, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327CrossRefPubMed

10.

He Q, Skog S, Tribukait B (1991) Cell cycle related studies on thymidine kinase and its isoenzymes in Ehrlich ascites tumours. Cell Prolif 24:3–14CrossRefPubMed

11.

Kauffman MG, Kelly TJ (1991) Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 11:2538–2546PubMed

12.

Ke PY, Chang ZF (2004) Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 24:514–526CrossRefPubMed

13.

He Q, Wang N, Skog S et al (1996) Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 70:117–124PubMed

14.

Gronowitz JS, Hagberg H, Källander CF et al (1983) The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin’s lymphoma. Br J Cancer 47:487–495PubMed

15.

O’Neill KL, Abram WP, McKenna PG (1986) Serum thymidine kinase levels in cancer patients. Ir J Med Sci 155:272–274CrossRefPubMed

16.

Gronowitz JS, Bergström R, Nou E et al (1990) Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer (Phila) 66:722–732CrossRef

17.

Bresnick E, Mayfield ED Jr, Liebelt AG et al (1971) Enzyme patterns in a group of transplantable mouse hepatomas of different growth rates. Cancer Res 31:743–751PubMed

18.

Broët P, Romain S, Daver A et al (2001) Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 19:2778–2787PubMed

19.

Foekens JA, Romain S, Look M et al (2001) Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61:1421–1425PubMed

20.

He Q, Skog S, Fornander T et al (2006) Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following operation of early breast cancer patients. Anticancer Res 26:4753–4760PubMed

21.

He Q, Zhang P, Zou L et al (2005) Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep 14:1013–1019PubMed

22.

Zhang J, Jia Q, Zou S et al (2006) Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15:455–461PubMed

23.

Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual. Springer, New YorkCrossRef

24.

Xu XH, Zhang YM, Shu XH et al (2008) Serological thymidine kinase 1 reflects progression of pre-malignant and malignant tumours during therapy. Mol Med Rep 1:705–711

25.

Wu CJ, Yang RJ, Zhou J et al (2003) Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277:157–169CrossRefPubMed

26.

Topolcan O, Holubeck L (2008) The role of thymidine kinase 1 in cancer diseases. Expert Opin Diagn 2:129–141CrossRef

27.

He Q, Zou L, Zhang PA, Lui JX et al (2000) The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. Int J Biol Markers 15:139–146PubMed

28.

Zou L, Zhang PG, Zou S et al (2002) The half-life of cytosolic thymidine kinase in serum by ECL dot bolt: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers 17:135–140PubMed

29.

Li HX, Zhang S, Lei DS et al (2005) Serum thymidine kinase 1 (STK1) is a prognostic and monitoring factor in patients with non-small-cell lung cancer. Oncol Rep 13:145–149PubMed

30.

HengZhi C, Zhou H, Tian NB et al (2008) Serological thymidine kinase 1 (STK1) indicates an elevated risk for development of malignant tumors. Anticancer Res 28:3897–3908

31.

Di Raimondo F, Giustolisi R, Lerner S et al (2001) Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol 12:621–625CrossRefPubMed

32.

Topolcan O, Holubec L Jr, Finek J et al (2005) Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. Anticancer Res 25:1831–1833PubMed

Titel: Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings
verfasst von: Yan Chen
Mingang Ying
YanSong Chen
Minhua Hu
Yingying Lin
Dedong Chen
Xiaoli Li
Ming Zhang
Xia Yun
Ji Zhou
Ellen He
Sven Skog
Publikationsdatum: 01.08.2010
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 4/2010
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0067-4

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings